| Haley Schexnayder Latour, PHARM D | |
|
4607 Veterans Memorial Blvd, Metairie, LA 70006-5323 | |
| (504) 457-4075 | |
| Not Available |
| Full Name | Haley Schexnayder Latour |
|---|---|
| Gender | Female |
| Speciality | Pharmacy - Community/retail Pharmacy |
| Location | 4607 Veterans Memorial Blvd, Metairie, Louisiana |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1043686264 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | E-14007 (Mississippi) | Secondary |
| 3336C0003X | Pharmacy - Community/retail Pharmacy | PST.023921 (Louisiana) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Haley Schexnayder Latour, PHARM D 5528 Rebecca Blvd, Kenner, LA 70065-1550 Ph: (504) 909-1892 | Haley Schexnayder Latour, PHARM D 4607 Veterans Memorial Blvd, Metairie, LA 70006-5323 Ph: (504) 457-4075 |
News Archive
Lowering exposure to allergens from mice may lead to improved lung growth for children with asthma living in low-income neighborhoods, helping them avoid lung ailments and possibly live longer, according to newly published research in The Journal of Allergy and Clinical Immunology.
Asteres Inc., the industry's leading provider of automated prescription pickup kiosks for retail, hospital, and Veterans Affairs/military pharmacies, announced today their first New Jersey hospital installation at Jersey Shore University Medical Center, a member of Meridian Health, in Neptune, New Jersey.
Two state attorneys general will face off at the National Press Club on the constitutionality of the health overhaul. In other news, a Mississippi district court judge has agreed to hear a different legal challenge to the measure.
Regado Biosciences, Inc., a biopharmaceutical company focused on the late-stage clinical development of its first-in-class, actively controllable antithrombotic drug system, REG1, today announced that the United States Food and Drug Administration has accepted the company's investigational new drug (IND) application for REG2. Regado previously completed a single escalating-dose Phase 1 clinical trial of REG2 and plans to conduct additional clinical testing in sub-acute venous thrombosis indications in the future.
› Verified 6 days ago